The Most Important DSCSA Updates for Manufacturers in 2021
While there may not be new DSCSA regulations going live in 2021, that doesn’t mean manufacturers can take a break from thinking about their DSCSA and serialization strategy this year. The 2023 requirements still loom ahead. In fact, [...]
New White Paper: Opportunities and Recent Trends for Biosimilars
Over the last year, biosimilars have seen increasing success in the US market. The number of biosimilars approved has accelerated, product sales for biosimilars are increasing, net prices are being driven down (for both brands and biosimilars), and [...]
Three Levels of Competitive Intelligence Research
Competitive intelligence is an extremely valuable step of any new drug or indication launch. From providing insight into a crowded market to guiding allocation of budget, this research is beneficial no matter what stage of the launch process [...]
Article Round Up: How the COVID-19 Outbreak is Impacting the Pharmaceutical Industry When Launching a New Drug
The COVID-19 pandemic is unprecedented and unpredictable. Nevertheless, we are remaining flexible as we continue to support pharmaceutical manufacturers and their life-changing work. Regardless of which stage you’re at in the drug development journey — from clinical trials to loss [...]
Why are some drug launches successful and some aren’t?
The launch of a new drug is a complex process. With so many factors playing into the final outcome, it may seem impossible to predict whether or not any given launch will be a success. While it’s true [...]
6 Examples of When Competitive Intelligence Should Be a Top Priority
The pharma industry can be complicated, but the more intel you have – market or competitive, the better you’ll be able to make decisions that lead you to success. Understanding what’s worked for your competitors, what hasn’t, where [...]